144 related articles for article (PubMed ID: 38280959)
1. Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer after Neoadjuvant Chemoradiotherapy: A Retrospective Study.
Li J; Zhou X; Liu Y; Zhu J; Wan G; Wang Y; Leng X; Han Y; Peng L; Wu L; Wang Q
Ann Surg Oncol; 2024 Jun; 31(6):3803-3812. PubMed ID: 38280959
[TBL] [Abstract][Full Text] [Related]
2. Impact of change in the Naples prognostic score after neoadjuvant chemoradiotherapy on survival in esophageal squamous cell carcinoma patients.
Zhang H; Xiao X; Luan S; Li X; Sun S; Yuan Y
Saudi Med J; 2024 May; 45(5):481-489. PubMed ID: 38734428
[TBL] [Abstract][Full Text] [Related]
3. Comparison of neoadjuvant chemotherapy or chemoradiotherapy plus immunotherapy for locally resectable esophageal squamous cell carcinoma.
Yang G; Yue H; Zhang X; Zeng C; Tan L; Zhang X
Front Immunol; 2024; 15():1336798. PubMed ID: 38779667
[TBL] [Abstract][Full Text] [Related]
4. EUS-derived maximum tumor thickness and tumor shrinkage rate as independent prognostic factors in locally advanced esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
Chen X; Chen X; Bao Y; Zhang W; Jiang L; Zhu J; Wang Y; Wu L; Wan G; Peng L; Han Y; Leng X; Wang Q; Zhao R
Endosc Ultrasound; 2023; 12(4):369-376. PubMed ID: 37795352
[TBL] [Abstract][Full Text] [Related]
5. Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
Ruan Y; Ma Y; Ma M; Liu C; Su D; Guan X; Yang R; Wang H; Li T; Zhou Y; Ma J; Zhang Y
J Transl Med; 2024 May; 22(1):471. PubMed ID: 38762454
[TBL] [Abstract][Full Text] [Related]
6. Immune cell patterns before and after neoadjuvant immune checkpoint blockade combined with chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Zheng DD; Li YY; Yuan XY; Lu JL; Zhang MF; Fu J; Zhang CZ
BMC Cancer; 2024 May; 24(1):649. PubMed ID: 38802821
[TBL] [Abstract][Full Text] [Related]
7. Primary gross tumor volume is prognostic and suggests treatment in upper esophageal cancer.
Chen Y; Huang Q; Chen J; Lin Y; Huang X; Wang Q; Yang Y; Chen B; Ye Y; Zheng B; Qi R; Chen Y; Xu Y
BMC Cancer; 2021 Oct; 21(1):1130. PubMed ID: 34670513
[TBL] [Abstract][Full Text] [Related]
8. Diffusion-weighted MRI and
Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
[TBL] [Abstract][Full Text] [Related]
9. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study.
Jiang L; Zhu J; Chen X; Wang Y; Wu L; Wan G; Han Y; Leng X; Peng L; Wang Q
Radiat Oncol; 2022 Dec; 17(1):218. PubMed ID: 36585731
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of fibroblast activation protein expressing tumor volume calculated from [
Zhao L; Pang Y; Chen S; Chen J; Li Y; Yu Y; Huang C; Sun L; Wu H; Chen H; Lin Q
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):593-601. PubMed ID: 36222855
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Neoadjuvant Chemoradiotherapy Followed by Surgery for Borderline Resectable Esophageal Squamous Cell Carcinoma.
Hirohata R; Hamai Y; Hihara J; Emi M; Kurokawa T; Yoshikawa T; Ohsawa M; Kitasaki N; Okada M
World J Surg; 2022 Aug; 46(8):1934-1943. PubMed ID: 35508816
[TBL] [Abstract][Full Text] [Related]
13. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J
JAMA Surg; 2021 Aug; 156(8):721-729. PubMed ID: 34160577
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of pathologically response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma: long term outcomes of a phase II study.
Tan Z; Yang H; Wen J; Luo K; Liu Q; Hu Y; Zhang L; Liu M; Yun J; Fu J
J Thorac Dis; 2018 Sep; 10(9):5254-5259. PubMed ID: 30416772
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of pre-therapeutic nutritional risk factors in elderly patients with locally advanced esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or radiotherapy.
Qiu J; Yang J; Yu Y; Wang Z; Lin H; Ke D; Zheng H; Li J; Yao Q
BMC Cancer; 2023 Jun; 23(1):597. PubMed ID: 37380982
[TBL] [Abstract][Full Text] [Related]
17. Gross Tumor Volume Predicts Survival and Pathological Complete Response of Locally Advanced Esophageal Cancer After Neoadjuvant Chemoradiotherapy.
Wang R; Zhou X; Liu T; Lin S; Wang Y; Deng X; Wang W
Front Oncol; 2022; 12():898383. PubMed ID: 35747837
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of postoperative radiotherapy for locally advanced esophageal squamous cell carcinoma.
Zhang Z; Xu L; Di X; Zhang C; Ge X; Sun X
Ann Palliat Med; 2019 Nov; 8(5):708-716. PubMed ID: 31865731
[TBL] [Abstract][Full Text] [Related]
19. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
20. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001).
Shang X; Zhao G; Liang F; Zhang C; Zhang W; Liu L; Li R; Duan X; Ma Z; Yue J; Chen C; Meng B; Ren X; Jiang H
Ann Transl Med; 2022 Feb; 10(4):229. PubMed ID: 35280363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
